Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4291 Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms

Introduction: Immune checkpoint inhibition (ICI) has activity in Grade 3 (G3) neuroendocrine neoplasms (NENs) but predictive biomarkers of overall survival (OS) are currently lacking.

Conference:

Presenting Author:

Authors: Brar T, Sukrithan V, Le D, Xu M, Olowookere C,

Keywords: Neuroendocrine Neoplasm, Immunotherapy, Ipilimumab, Nivolumab, Immune checkpoint inhibitor, biomarker, genomic score,

#4003 Neuroendocrine differentiation in gastric cancer: Epidemiological insights and therapeutic implications

Introduction: Gastric cancer (GC) with neuroendocrine differentiation (NED) represents a significant yet understudied subset, accounting for 10-40% of cases. The absence of tailored clinical guidelines highlights the urgent need for specialized treatment approaches.

Conference:

Presenting Author:

Authors: Huang Z, Wei J, Shen Y, Zhang J,

Keywords: Neuroendocrine Differentiation, Epidemiological, Treatment, Surufatinib,

#3933 Surufatinib plus Sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN): A multicenter, single arm phase 2 study

Introduction: Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor). Preclinical and clinical studies have shown that SUR is the best partner of immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Wang Y, Li J, Shen L, Lu M,

Keywords: Surufatinib, Sintilimab, IBI310, high-grade advanced-neuroendocrine neoplasm,

#3289 Short-interval, low-dose (SILD) Lu-177 DOTAiTATE therapy to overcome resistance to immunotherapy with PD-1 checkpoint inhibitors: Proof of concept to induce remission in patients with metastatic Merkel cell carcinoma and melanoma

Introduction: Immunotherapy with PD-1 immune checkpoint inhibitors (ICI) in Merkel cell carcinoma (MCC) or melanoma have proven efficacy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Aicher A, Sindrilaru A, Beer A, Prasad V,

Keywords: PRRT, SILD, ICI, Merkel cell carcinoma, melanoma, tumor microenvironment remodelling,

#3160 Efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine cancer: A single-center retrospective study

Introduction: Neuroendocrine carcinoma is a group of poorly differentiated and highly malignant tumors. There is no standard follow-up treatment regimen after the failure of first-line treatment.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Song L, Yu X,

Keywords: immune checkpoint inhibitor, anlotinib, neuroendocrine carcinoma,